Saroglitazar

Name: Saroglitazar
Brand: MedChemExpress
SKU: HY-19937
Rating: 5.0 (10 reviews)

Cat. No.: HY-19937: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Saroglitazar is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC₅₀ values of 0.65 pM and 3 nM in HepG2 cells, respectively.

For research use only. We do not sell to patients.

CAS No. : 495399-09-2

Size	Stock	Quantity
Oil + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	Get quote	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	Get quote	Estimated Time of Arrival: December 31
Oil
1 mg	Get quote 9 - 11 weeks 8 - 10 weeks 10 - 12 weeks 8 - 10 weeks	Estimated Time of Arrival: December 31
5 mg	Get quote 9 - 11 weeks 8 - 10 weeks 10 - 12 weeks 8 - 10 weeks	Estimated Time of Arrival: December 31
10 mg	Get quote 9 - 11 weeks 8 - 10 weeks 10 - 12 weeks 8 - 10 weeks	Estimated Time of Arrival: December 31
25 mg	Get quote 9 - 11 weeks 8 - 10 weeks 10 - 12 weeks 8 - 10 weeks	Estimated Time of Arrival: December 31
50 mg	Get quote 9 - 11 weeks 8 - 10 weeks 10 - 12 weeks 8 - 10 weeks	Estimated Time of Arrival: December 31
100 mg	Get quote 9 - 11 weeks 8 - 10 weeks 10 - 12 weeks 8 - 10 weeks	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 10 publication(s) in Google Scholar

Other Forms of Saroglitazar:

Saroglitazar magnesium In-stock
Saroglitazar-d₄ Get quote

10 Publications Citing Use of MCE Saroglitazar

Histological Imaging/Staining

RT-PCR

ELISA

: Saroglitazar purchased from MedChemExpress. Usage Cited in: Medicina (Kaunas). 2025 Jun 26;61(7):1157. [Abstract]; HE staining of lung tissue in control, BLM, and BLM mice treated with SGZ (10 mg/kg, p.o.).

: Saroglitazar purchased from MedChemExpress. Usage Cited in: Medicina (Kaunas). 2025 Jun 26;61(7):1157. [Abstract]; IF staining of collagen 1 of lung tissue in control, BLM, and BLM mice treated with SGZ (10 mg/kg, p.o.).

: Saroglitazar purchased from MedChemExpress. Usage Cited in: Medicina (Kaunas). 2025 Jun 26;61(7):1157. [Abstract]; Western blot analysis of lung tissue of control, BLM, and BLM mice treated with SGZ (10 mg/kg, p.o.).

: Saroglitazar purchased from MedChemExpress. Usage Cited in: Medicina (Kaunas). 2025 Jun 26;61(7):1157. [Abstract]; PCR analysis of IL-1β, IL-6, and TNF-α in RAW264.7 treated with BLM and SGZ (10 μM).

: Saroglitazar purchased from MedChemExpress. Usage Cited in: Medicina (Kaunas). 2025 Jun 26;61(7):1157. [Abstract]; ELISA analysis of IL-1β, IL-6, and TNF-α of RAW264.7 treated with BLM and SGZ (10 μM).

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All PPAR Isoform Specific Products:

View All Isoforms

PPARα PPARβ/δ PPARγ PPAR PPARδ

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]

PPARα

0.65 pM (EC₅₀, HepG2 cell)

PPARγ

3 nM (EC₅₀, HepG2 cell)

In Vivo

In db/db mice, 12-day treatment with Saroglitazar (0.01-3 mg/kg per day, orally) causes dose-dependent reductions in serum triglycerides (TG), free fatty acids (FFA), and glucose. The ED₅₀ for these effects is found to be 0.05, 0.19, and 0.19 mg/kg, respectively with highly significant (91%) reduction in serum insulin and AUC-glucose following oral glucose administration (59%) at 1 mg/kg dose. A 90-day repeated dose comparative study in Wistar rats and marmosets confirms efficacy (TG lowering) potential of Saroglitazar and has indicated low risk of PPAR-associated side effects in humans. Based on efficacy and safety profile, Saroglitazar appears to have good potential as novel^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

439.57

Formula

C₂₅H₂₉NO₄S

CAS No.

495399-09-2

Appearance

Oil

Color

Yellow to brown

SMILES

OC([C@@H](OCC)CC1=CC=C(OCCN2C(C)=CC=C2C3=CC=C(SC)C=C3)C=C1)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Pure form	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (113.75 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.2750 mL	11.3748 mL	22.7495 mL
5 mM	0.4550 mL	2.2750 mL	4.5499 mL
10 mM	0.2275 mL	1.1375 mL	2.2750 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.69 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.69 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (5.69 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 98.22%

Select Batch:

Data Sheet (275 KB) SDS (394 KB)

COA (249 KB) HNMR (238 KB) LCMS (112 KB)

Handling Instructions (2659 KB)

References

[1]. Jain MR, et al. Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models. Pharmacol Res Perspect. 2015 Jun;3(3):e00136. [Content Brief]

Animal Administration
^[1]

Rats: Rats randomize based on body weights and are divided into three equal groups and receives the daily administration of vehicle (50% w/v honey for marmoset and 0.1% carboxymethylcellulose for Wistar rats) or Saroglitazar (1.5 and 15 mg/kg per day) for 90 days by oral gavage^[1].

Mice: Male C57BL/6J-db/db mice are bled on day 0 to determine pretreatment serum glucose and TG. During next 12 days, each animal is dosed (by oral gavage) with vehicle (0.5% sodium carboxymethyl cellulose) or Saroglitazar (0.01, 0.03, 0.1, 0.3,1, and 3 mg/kg per day) or pioglitazone (60 mg/kg per day) and on day 12 of the treatment, blood samples are collected (1 h after dosing) from orbital sinus under light ether anesthesia. The serum is isolated and analyzed for glucose, TG, free fatty acid (FFA), and insulin levels^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References

[1]. Jain MR, et al. Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models. Pharmacol Res Perspect. 2015 Jun;3(3):e00136. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.2750 mL	11.3748 mL	22.7495 mL	56.8738 mL
	5 mM	0.4550 mL	2.2750 mL	4.5499 mL	11.3748 mL
	10 mM	0.2275 mL	1.1375 mL	2.2750 mL	5.6874 mL
	15 mM	0.1517 mL	0.7583 mL	1.5166 mL	3.7916 mL
	20 mM	0.1137 mL	0.5687 mL	1.1375 mL	2.8437 mL
	25 mM	0.0910 mL	0.4550 mL	0.9100 mL	2.2750 mL
	30 mM	0.0758 mL	0.3792 mL	0.7583 mL	1.8958 mL
	40 mM	0.0569 mL	0.2844 mL	0.5687 mL	1.4218 mL
	50 mM	0.0455 mL	0.2275 mL	0.4550 mL	1.1375 mL
	60 mM	0.0379 mL	0.1896 mL	0.3792 mL	0.9479 mL
	80 mM	0.0284 mL	0.1422 mL	0.2844 mL	0.7109 mL
	100 mM	0.0227 mL	0.1137 mL	0.2275 mL	0.5687 mL

Saroglitazar Related Classifications

Metabolic Disease

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Saroglitazar495399-09-2PPARPeroxisome proliferator-activated receptorsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Saroglitazar

Customer Review

Other Forms of Saroglitazar:

Saroglitazar Related Antibodies

10 Publications Citing Use of MCE Saroglitazar

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All PPAR Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Saroglitazar Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report